Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. After two generics makers filed for potential FDA approvals of copycat Evrysdi products, Roche isn't taking the threat lying down.